**Supplementary Table S1.** Clinicopathological features of the patients with GIST in this study.

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Untreated** | **Sensitive** | **Resistant** |
| **Number of patients** | 36 | 30 | 19 |
| **Number of specimens** | 36 | 38 | 32 |
| **Median age (range)** | 62 (27-81) | 60 (24-83) | 53 (28-76) |
| **Female** | 21 | 17 | 11 |
| **Male** | 15 | 13 | 8 |
| **Primary** | 33 | 14 | 1 |
| **Metastatic** | 3 | 24 | 31 |
| **Tyrosine kinase inhibitor (most recent)** |  |  |  |
| Imatinib | Not applicable | 29 | 2 |
| Sunitinib | Not applicable | 0 | 7 |
| Multiple | Not applicable | 0 | 7 |
| Unavailable | Not applicable | 1 | 3 |
| **Median cumulative duration of treatment (months)** | Not applicable | 8.5 (0.75-48) | 36 (5-120) |
| **Mutation of tumor specimen** |  |  |  |
| *KIT* exon 9 | 1 | 0 | 4 |
| *KIT* exon 11 | 18 | 20 | 12 |
| *PDGFRA* | 2 | 2 | 0 |
| Wild type | 2 | 0 | 3 |
| Other/Unavailable | 13 | 8 | 0 |